Sanofi $SNY Shares Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA grew its holdings in shares of Sanofi (NASDAQ:SNY) by 8.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 678,092 shares of the company’s stock after purchasing an additional 54,081 shares during the period. Pictet Asset Management Holding SA’s holdings in Sanofi were worth $31,680,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Flagship Harbor Advisors LLC acquired a new position in shares of Sanofi in the fourth quarter valued at approximately $25,000. Measured Wealth Private Client Group LLC acquired a new stake in Sanofi during the 3rd quarter worth approximately $29,000. Palisade Asset Management LLC acquired a new stake in Sanofi during the 3rd quarter worth approximately $30,000. Annis Gardner Whiting Capital Advisors LLC boosted its position in Sanofi by 544.4% in the 4th quarter. Annis Gardner Whiting Capital Advisors LLC now owns 696 shares of the company’s stock valued at $34,000 after buying an additional 588 shares during the period. Finally, Purpose Unlimited Inc. acquired a new position in shares of Sanofi in the fourth quarter worth $36,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Analysts Set New Price Targets

SNY has been the topic of a number of recent research reports. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Argus raised Sanofi to a “strong-buy” rating in a research note on Monday, April 27th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. Weiss Ratings raised Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Finally, Morgan Stanley set a $52.00 price objective on Sanofi in a research note on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $51.00.

Sanofi Stock Performance

Shares of SNY stock opened at $42.66 on Wednesday. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. The firm has a fifty day moving average price of $43.97 and a 200 day moving average price of $45.95. The company has a market cap of $103.43 billion, a P/E ratio of 11.92, a PEG ratio of 1.07 and a beta of 0.34. Sanofi has a 12 month low of $40.89 and a 12 month high of $52.68.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which was paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th were issued a dividend of $2.4225 per share. This is a positive change from Sanofi’s previous annual dividend of $2.04. The ex-dividend date of this dividend was Monday, May 4th. This represents a yield of 559.0%. Sanofi’s dividend payout ratio (DPR) is presently 49.16%.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.